Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

The phase 3, randomized Frontline Investigation of Revlimid and Dexamethasone Versus Standard Thalidomide (FIRST) trial investigating lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous) vs melphalan, prednisone and thalidomide for 12 cycles (MPT) and Rd for 18 cycles (...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahlis, N J, Corso, A, Mugge, L-O, Shen, Z-X, Desjardins, P, Stoppa, A-M, Decaux, O, de Revel, T, Granell, M, Marit, G, Nahi, H, Demuynck, H, Huang, S-Y, Basu, S, Guthrie, T H, Ervin-Haynes, A, Marek, J, Chen, G, Facon, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668494/
https://www.ncbi.nlm.nih.gov/pubmed/28373701
http://dx.doi.org/10.1038/leu.2017.111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668494/
https://www.ncbi.nlm.nih.gov/pubmed/28373701
http://dx.doi.org/10.1038/leu.2017.111

Ejemplares similares